Every	ب م		्रा स्था		1652
A SULL COLL			U.S. Pater	nt and Ti	PTO/SB/21 (03-03) Approved for use through 04/30/2003. OMB 0651-0031 rademark Office; U.S. DEPARTMENT OF COMMERCE
Application Number Application Number 09/909,077					
TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Filing Date		9/2001 FCF/1/2	
		First Named Inventor		k Arasappan AUC	
		Art Unit	1653	TECH 05 ? 2002	
		Examiner Name	David	d Lukton	
Total Number of Pages in This Submission 14		14	Attorney Docket Number	09/909,077 07/19/2001 Ashok Arasappan 1653 David Lukton IN01156	
ENCLOSURES (Check all that apply)					
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts Index 37 CER 1 52 or 1 53		Remar Also ea (1) Ma (2) Res (3) Sec	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s)		After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): Certificate of Mailing (1pg.); Post Card; * Please see Remarks section
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm or Individual Palaiyur S. Kalyanaraman, Reg. No. 34,634					
Signature Date	+ Der				
07/31/2003					
CERTIFICATE OF TRANSMISSION/MAILING					
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:					

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Date

Typed or printed

Signature

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Attorney Docket No.: IN01156 Application No.: 09/909,077

Filing Date: 07/19/2001 Inventor: Arasappan et al.

PTO/SB92 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Certificate of Mailing under 37 CFR 1.8

RECEIVED

AUG 0 7 2003
TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450 Mailstop: Non Fee Amendment

Date

Signature

Palaiyur S. Kalyanaraman, Reg. No. 34,634

Typed or printed name of person of signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Documents submitted:

Response Transmittal - 1pg.; Amendment - 3pgs

Marked-Up Amendment - 2pgs.

Response to Restriction Requirement and Sequence Listing - 3pgs.

Sequence Listing - 4pgs.

Sequence Listing on Floppy - 1 diskette; Post Card; Certificate of Mailing

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PATENT: IN01156

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

A. Arasappan *et al.*Serial No.: 09/909,077

PECEIVED

AUG 0 72003

TECH CENTER 1600/2000

Filed: July 19, 2001) Atty. Docket No.: IN01156

For: Novel Imidazolidinones as NS3-Serine Protease Inhibitors of Hepatitis C

Virus

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT AND SEQUENCE LISTING

Sir:

This communication is an Amendment and a response to the restriction requirement issued by the Examiner on July 15, 2003, in the above-identified patent application. Included in this communication are: a response to restriction requirement, an amendment to satisfy sequence listing, a sequence listing and a floppy disk containing said sequence listing.

Claims 1-47 are currently pending in the application. The Examiner restricted the claims into four groups (as subgenera) and twelve inventions: Group 1 (R1 limited to COR^5 , and R^5 is limited to $N(R^9)(R^{10})$); Group 2 (R^1 being moieties other than in Group 1); Group 3 (X limited to carbonyl or thiocarbonyl); and Group 4 (X limited to $C[(R)(R')]_p$). The claims were divided up into 12 different ways to match the four groups.

Applicants are puzzled by these restrictions. Applicants believe that all claims 1-47 form part of one and the same invention. Applicants believe that when there is a linking claim (claim 1 here) encompassing the scope of all the processes, uses, composition and compounds, it is inappropriate to restrict the invention into these various inventions. Applicants also believe that due to such commonality, a complete examination of claims 1-47 as filed would not cause undue burden. Applicants further believe that the same art search will most probably apply to the alleged separate inventions, and respectfully submits that the restriction is improper.

Under the statute "two or more independent and distinct inventions.... in one application may.... be restricted to one of the inventions." Inventions are "independent" if "there is no disclosed relationship between two or more subjects disclosed" (MPEP 802.01). The term "distinct" means that "two or more subjects as disclosed are related.... but are capable of separate manufacture, use or sale as claimed, and are patentable over each other" (MPEP 802.01). However, even when patentably distinct inventions, restriction is not required unless one of the following reasons appear (MPEP 808.02):

- 1. Separate classification
- 2. Separate status in the art; or
- 3. Different field of search.

In the present application, Applicants believe that the Examiner has not established a clear reason to establish the existence of any of the above 4 groups and 12 patentably distinct inventions. Reconsideration and withdrawal of the restriction requirement are, therefore, respectfully requested.

Furthermore, in order to comply with the Examiner's requirement, Applicants are electing, with traverse, the invention cited as Invention No. 3 by the Examiner as limited to groups 2 and 3. Applicants believe that this should also appropriately include the inventions classified as Invention Nos. 6, 7, 10 and 11 by the Examiner. Additionally, in order to comply with the requirement that a species be elected for examination purposes, Applicant is electing the following compound:

The above-shown compound occurs in Table 9 on page 67 of the application, as well as in Claim 43 (Compound No. 57).

Also enclosed herewith are an Amendment to satisfy the sequence listing, a Marked-up amendment and a sequence listing (paper copy and CRF on diskette).

If the Examiner has questions, the Examiner is invited to contact the undersigned.

Respectfully submitted,

Dr. Palaiyur S. Kalyanaraman Registration No. 34,634 Attorney for Applicants Tel: 908-298-5068

Fax: 908-298-5388